Retatrutide + Cagrilintide Bundle

Retatrutide + Cagrilintide Research Bundle brings together two separate investigational research peptides representing different metabolic signalling pathways.

Cagrilintide is a long-acting amylin receptor agonist currently being investigated within research involving weight loss, satiety, appetite regulation and metabolic signalling.

Retatrutide is an investigational triple receptor agonist targeting the GLP-1, GIP and glucagon receptors and is being studied within weight-loss and metabolic research.

Two Distinct Research Pathways

Cagrilintide
→ Amylin pathway

Retatrutide
→ GLP-1 + GIP + glucagon pathways

The bundle brings together two distinct metabolic research pathways within one research bundle.

Available Bundle Configurations

Retatrutide 20 mg + Cagrilintide 10 mg
€179.95

Retatrutide 30 mg + Cagrilintide 10 mg
€199.95

Retatrutide 50 mg + Cagrilintide 10 mg
€259.95

Each bundle consists of two separate lyophilised research peptide vials.

Research Areas

• Weight-loss research
• Metabolic research
• Appetite and satiety research
• Energy balance
• Amylin receptor signalling
• GLP-1 receptor signalling
• GIP receptor signalling
• Glucagon receptor signalling
• Multi-pathway metabolic research

Product Information

Product:
Retatrutide + Cagrilintide Research Bundle

Format:
Two separate lyophilised research peptide vials

Cagrilintide:
10 mg

Retatrutide:
20 mg, 30 mg or 50 mg depending on selected variation

Category:
Research Peptide Bundle

Research Area:
Weight Loss & Metabolic Research

Both Retatrutide and Cagrilintide are individually being investigated within scientific and clinical research.

The specific combination of Retatrutide and Cagrilintide is not an approved or clinically proven combination therapy.

For research purposes only. Not intended for human consumption.